C Matthieu - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

C Matthieu

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

Journal of Internal Medicine|December 4, 2003

A young man with a renal colicF Barbey, C Matthieu, G Nseir, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 8, 2008

p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classesF-C Bidard, M-C Matthieu, P Chollet, et al.

Breast Cancer Research and Treatment|September 5, 2016

BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapyA S Hamy, I Bieche, J Lehmann-Che, et al.

Pageof 1

Search research articles

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

Journal of Internal Medicine|December 4, 2003

A young man with a renal colicF Barbey, C Matthieu, G Nseir, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 8, 2008

p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classesF-C Bidard, M-C Matthieu, P Chollet, et al.

Breast Cancer Research and Treatment|September 5, 2016

BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapyA S Hamy, I Bieche, J Lehmann-Che, et al.

Pageof 1